Hexarelin

Hexarelin is a synthetic hexapeptide belonging to the growth hormone-releasing peptides (GHRPs) family. It is known for its potent ability to stimulate the release of growth hormone (GH) from the pituitary gland, making it a valuable tool in research and potential therapeutic applications. Hexarelin has been studied for its effects on muscle growth, fat loss, and overall physical performance, as well as its potential benefits in cardiovascular health.

Category

Growth Hormone Secretagogue

Sequence

H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2

Molecular Weight

Approximately 887.04 g/mol

Molecular Formula

C47H58N12O6

Half Life

Ranging From 55 to 70 Minutes

Most Common Uses

Hexarelin is primarily used in research settings to explore its effects on growth hormone secretion. Researchers administer it to study its potential in enhancing muscle growth, improving recovery from injuries, and supporting tissue repair due to its ability to stimulate the release of growth hormone from the pituitary gland. In experimental contexts, Hexarelin is investigated for its role in addressing growth hormone deficiencies, particularly in models of hormonal imbalances.

Its use extends to exploring benefits in bone density improvement and cardiac function, as it may enhance cardiac performance in certain preclinical studies. Typically administered via subcutaneous or intramuscular injection, Hexarelin remains a research peptide, with clinical applications limited by regulatory restrictions in many regions. Ongoing studies continue to evaluate its therapeutic potential in various physiological systems.

Mechanism of Action

Hexarelin functions as a potent growth hormone secretagogue by targeting the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus. Upon binding to these receptors, it stimulates the release of growth hormone in a dose-dependent manner, leading to increased circulating levels of insulin-like growth factor-1 (IGF-1), which supports tissue growth and repair. Hexarelin also enhances prolactin and cortisol secretion to a lesser extent, influencing metabolic and stress responses.

Its activation of ghrelin receptors in cardiac tissue may improve cardiac function by enhancing contractility and reducing apoptosis in heart muscle cells. Unlike native ghrelin, Hexarelin exhibits greater resistance to enzymatic degradation, allowing sustained activity with a half-life ranging from 55 to 70 minutes. These actions make it a valuable tool in research for exploring growth hormone dynamics and potential therapeutic applications in muscle, bone, and cardiovascular systems.

Structure and Pharmacology

Hexarelin is a synthetic hexapeptide with the amino acid sequence H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2 (one-letter code: HwAWfK-NH2). Its molecular formula is C47H58N12O6, and it has a molecular weight of 887 g/mol. The peptide features a C-terminal amidation, which enhances its stability against enzymatic degradation. The inclusion of D-amino acids, such as D-tryptophan and D-phenylalanine, along with a methylated tryptophan residue, increases its resistance to breakdown, prolonging its activity compared to natural peptides. This structural design allows Hexarelin to effectively interact with specific receptors in the body, supporting its role as a growth hormone secretagogue.

Pharmacologically, Hexarelin acts primarily as a potent agonist of the ghrelin receptor (GHS-R1a), located in the pituitary gland and hypothalamus. By binding these receptors, it stimulates the release of growth hormone in a dose-dependent manner, which in turn promotes the production of insulin-like growth factor-1 (IGF-1), aiding tissue growth and repair. The peptide also modestly increases prolactin and cortisol levels, influencing metabolic and stress-related pathways. Its effects extend to cardiac tissue, where activation of ghrelin receptors may enhance contractility and protect against apoptosis, suggesting potential benefits for cardiovascular function.

Hexarelin’s resistance to enzymatic degradation results in a half-life ranging from 55 to 70 minutes, allowing sustained activity following subcutaneous or intramuscular injection. Typically used in research settings, its pharmacokinetic profile supports short-term dosing regimens to explore applications in muscle growth, bone density improvement, and cardiac health, though clinical use remains limited due to regulatory restrictions in many regions.

Hexarelin Dosage

Hexarelin is administered through subcutaneous or intramuscular injection to study its growth hormone-releasing effects. Typical doses in experimental protocols range from 1 to 2 micrograms (mcg) per kilogram of body weight, given one to three times daily. For an average adult, this translates to approximately 70 to 300 mcg per subcutaneous (SC) injection, depending on body weight and research objectives. Treatment cycles often span 7 to 14 days, with breaks of similar duration to prevent receptor desensitization.

Researchers dissolve the lyophilized peptide in sterile water or saline before administration to ensure proper delivery. Dosing regimens vary based on the specific goals of the study, such as investigating muscle growth, tissue repair, or cardiac function, and require careful monitoring to assess physiological responses. Clinical use remains limited due to regulatory restrictions in many regions.

Warnings and Cautions

Hexarelin requires careful administration due to potential risks associated with its growth hormone-releasing effects. Those with known hypersensitivity to Hexarelin or its components should avoid its use, as allergic reactions, such as rash or swelling, may occur and necessitate immediate medical attention. Patients with pre-existing conditions like pituitary tumors or adrenal disorders need close monitoring, as Hexarelin’s stimulation of growth hormone, prolactin, and cortisol may exacerbate these conditions. Pregnant or breastfeeding women should avoid using Hexarelin, as safety data in these populations are limited.

Prolonged or excessive dosing may lead to receptor desensitization, reducing the peptide’s effectiveness. Common side effects include injection site irritation, fatigue, or headaches, and persistent symptoms warrant medical evaluation. Hexarelin’s use is restricted in many regions due to limited clinical approval, and administration should occur under strict medical or research supervision to ensure safety.

Research & Clinical Trials

Growth Hormone in Long-Term Hexarelin Therapy

The Cardiovascular Action of Hexarelin

Hexarelin & Growth Hormone-Releasing Activity in Humans

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Rahim, A., O’Neill, P. A., & Shalet, S. M. (1998). Growth hormone status during long-term hexarelin therapy. The Journal of Clinical Endocrinology & Metabolism, 83(5), 1644–1649. https://doi.org/10.1210/jcem.83.5.4812

[2] Mao, Y., Tokudome, T., & Kishimoto, I. (2014). The cardiovascular action of hexarelin. Journal of geriatric cardiology : JGC, 11(3), 253–258. https://doi.org/10.11909/j.issn.1671-5411.2014.03.007

[3] Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., Lenaerts, V., Wüthrich, P., & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans. A dose-response study. European journal of clinical pharmacology, 46(5), 421–425. https://doi.org/10.1007/BF00191904

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?